Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres

Digestive and Liver Disease

Volumn 46, Issue 11, 2014, Pages 985-990

  Mandel, Michael D ^a   Balint, Anita ^b   Golovics, Petra A ^a   Vegh, Zsuzsanna ^a   Mohas, Anna ^a   Szilagyi, Blanka ^a   Szabo, Agnes ^a   Kurti, Zsuzsanna ^a   Kiss, Lajos S ^a   Lovasz, Barbara D ^a   Gecse, Krisztina B ^a   Farkas, Klaudia ^b   Molnar, Tamas ^b   Lakatos, Peter L ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Adalimumab; Anti TNF infliximab; CD; Hospitalization; Risk; Surgery; UC

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; STEROID; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANUS DISEASE; ARTICLE; BIOLOGICAL THERAPY; COLON SURGERY; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; GENDER; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT HISTORY OF SURGERY; PATIENT REFERRAL; PATIENT RISK; PHENOTYPE; RETROSPECTIVE STUDY; TIME TO TREATMENT; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS, ULCERATIVE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION STUDY; HUNGARY; INCIDENCE; LENGTH OF STAY; MIDDLE AGED; MULTICENTER STUDY; RISK; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TIME; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HUNGARY; IMMUNOLOGIC FACTORS; INCIDENCE; LENGTH OF STAY; MIDDLE AGED; ODDS RATIO; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84908220857     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.07.168     Document Type: Article

References (38)

1. Odes S., Vardi H., Friger M., et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006, 131:719-728.
2. Dinesen L.C., Walsh A.J., Protic M.N., et al. The pattern and outcome of acute severe colitis. Journal of Crohn's and Colitis 2010, 4:431-437.
3. Ananthakrishnan A.N., Issa M., Beaulieu D.B., et al. History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflammatory Bowel Diseases 2009, 15:176-181.
4. Bernstein C.N., Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. American Journal of Gastroenterology 2006, 101:110-118.
5. Molnár T., Farkas K., Nyári T., et al. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. Journal of Gastrointestinal and Liver Diseases 2011, 20:359-363.
6. Wolters F.L., Russel M.G.V.M., Stockbrugger R.W. Systematic review: has disease outcome in Crohn's disease changed during the last four decades. Alimentary Pharmacology and Therapeutics 2004, 20:483-496.
7. Bernstein C.N., Loftus E.V., Ng S.C., et al. Epidemiology and natural history task force of the international organization for the study of inflammatory bowel disease (IOIBD). Hospitalisations and surgery in Crohn's disease. Gut 2012, 61:622-629.
8. Lakatos P.L., Golovics P.A., David G., et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. American Journal of Gastroenterology 2012, 107:579-588.
9. Burisch J., Jess T., Martinato M., et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis 2013, 7:322-337.
10. Van Assche G., Vermeire S., Rutgeerts P. The potential for disease modification in Crohn's disease. Nature Reviews Gastroenterology and Hepatology 2010, 7:79-85.
11. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
12. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
13. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
14. Costa J., Magro F., Caldeira D., et al. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflammatory Bowel Diseases 2013, 19:2098-2110.
15. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1989, 24(Suppl. 170):2-6.
16. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology 2005, 19(Suppl. A):5-36.
17. Stange E.F., Travis S.P.L., Vermeire S., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006, 55(Suppl. I):i1-i15.
18. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
19. Szamosi T., Banai J., Lakatos L., et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and non-smokers with Crohn's disease, while smoking prevents colectomy in UC. European Journal of Gastroenterology and Hepatology 2010, 22:872-879.
20. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
21. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine 2004, 350:876-885.
22. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005, 353:2462-2476.
23. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Annals of Internal Medicine 2007, 146:829-838.
24. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
25. Carter C.T., Leher H., Smith P., et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. American Journal of Managed Care 2011, 17:385-392.
26. Feagan B.G., Panaccione R., Sandborn W.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
27. Panaccione R., Colombel J.F., Sandborn W.J., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics 2010, 31:1296-1309.
28. Feagan B.G., Sandborn W.J., Lazar A., et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014, 146:110-118.
29. Ha C., Ullman T.A., Siegel C.A., et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clinical Gastroenterology and Hepatology 2012, 10:1002-1007.
30. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
31. Lindsay J.O., Chipperfield R., Giles A., et al. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease. Alimentary Pharmacology and Therapeutics 2013, 38:52-61.
32. Riis A., Martinsen T.C., Waldum H.L., et al. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scandinavian Journal of Gastroenterology 2012, 47:649-657.
33. Leombruno J.P., Nguyen G.C., Grootendorst P., et al. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiology and Drug Safety 2011, 20:838-848.
34. Sprakes M.B., Ford A.C., Suares N.C., et al. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Alimentary Pharmacology and Therapeutics 2010, 32:1357-1363.
35. Carter C.T., Waters H.C., Smith D.B. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs. Advances in Therapy 2011, 28:671-683.
36. Loomes D.E., Teshima C., Jacobs P., et al. Health care resource use and costs in Crohn's disease before and after infliximab therapy. Canadian Journal of Gastroenterology 2011, 25:497-502.
37. Lakatos L., Kiss L.S., David G., et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflammatory Bowel Diseases 2011, 17:2558-2565.
38. Munkholm P., Langholz E., Davidsen M., et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scandinavian Journal of Gastroenterology 1995, 30:699-770.